Cantor Fitzgerald raised the price target for the Beam Therapeutics Inc. (NASDAQ:BEAM) stock to “an Overweight”. The rating was released on February 01, 2023, according to finviz. We previously noted in another research note published on December 20, 2022 by BMO Capital Markets that upgraded the stock from a Market perform to an Outperform with a price target of $66 for BEAM stock. The research report from Citigroup has initiated the stock to Buy, with a price target set at $62. The stock was initiated by BMO Capital Markets, who disclosed in a research note on June 17, 2022, to Market Perform and set the price objective to $41. In their research brief published April 28, 2022, Credit Suisse analysts initiated the Beam Therapeutics Inc. stock to Neutral with a price target of $62.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of Beam Therapeutics Inc. (NASDAQ:BEAM) raised 1.17% to close Thursday’s market session at $35.51, higher as compared to yesterday’s close. The stock price fluctuated between $34.58 and $36.14 throughout the trading session with the volume trading being 919521 shares, which represented a significant variation when compared to the three months average volume of 899.57K shares. The firm’s stock price fluctuated 2.01% within the last five trades and -17.26% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -37.52% in the last 6 months and -22.37% was subtracted to its value over the previous 3 months. BEAM stock is trading at a margin of -7.42%, -14.21% and -24.38% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
As of the close of trading, BEAM deals in the Healthcare domain. The stock is trading -51.54 percent below its 52-week high and 27.87 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -46. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Beam Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $2.78 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 45.72 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 3.43, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.50 percent of Beam Therapeutics Inc. shares are owned by insiders, and 87.10 percent are held by financial institutions. Burrell Terry-Ann, the Chief Financial Officer at Beam Therapeutics Inc. (BEAM) has sold 36,152 shares of firm on Jan 27 at a price of $45.08 against the total amount of $1.63 million. In another inside trade, Burrell Terry-Ann, Chief Financial Officer of Beam Therapeutics Inc. (NASDAQ:BEAM) sold 1,102 shares of the firm on Jan 26 for a total worth of $49763.0 at a price of $45.16. An inside trade which took place on Jan 24, Chief Financial Officer of Beam Therapeutics Inc. Burrell Terry-Ann sold 14,810 shares of firm against total price of $0.67 million at the cost of $45.01 per share.